Suppr超能文献

相似文献

1
Hypoxia Induces Resistance to EGFR Inhibitors in Lung Cancer Cells via Upregulation of FGFR1 and the MAPK Pathway.
Cancer Res. 2020 Nov 1;80(21):4655-4667. doi: 10.1158/0008-5472.CAN-20-1192. Epub 2020 Sep 1.
2
Overcoming acquired resistance of gefitinib in lung cancer cells without T790M by AZD9291 or Twist1 knockdown in vitro and in vivo.
Arch Toxicol. 2019 Jun;93(6):1555-1571. doi: 10.1007/s00204-019-02453-2. Epub 2019 Apr 16.
8
Hypoxia Promotes Resistance to EGFR Inhibition in NSCLC Cells via the Histone Demethylases, LSD1 and PLU-1.
Mol Cancer Res. 2018 Oct;16(10):1458-1469. doi: 10.1158/1541-7786.MCR-17-0637. Epub 2018 Jun 22.

引用本文的文献

3
Strategies to Overcome Resistance to Osimertinib in EGFR-Mutated Lung Cancer.
Int J Mol Sci. 2025 Mar 25;26(7):2957. doi: 10.3390/ijms26072957.
4
Unraveling the triad of hypoxia, cancer cell stemness, and drug resistance.
J Hematol Oncol. 2025 Mar 18;18(1):32. doi: 10.1186/s13045-025-01684-4.
5
Optimizing Osimertinib for NSCLC: Targeting Resistance and Exploring Combination Therapeutics.
Cancers (Basel). 2025 Jan 29;17(3):459. doi: 10.3390/cancers17030459.
6
Prioritizing Context-Dependent Cancer Gene Signatures in Networks.
Cancers (Basel). 2025 Jan 3;17(1):136. doi: 10.3390/cancers17010136.
7
Canonical and noncanonical NOTCH signaling in the nongenetic resistance of cancer: distinct and concerted control.
Front Med. 2025 Feb;19(1):23-52. doi: 10.1007/s11684-024-1107-1. Epub 2025 Jan 2.
10
3D cell culture models in research: applications to lung cancer pharmacology.
Front Pharmacol. 2024 Sep 23;15:1438067. doi: 10.3389/fphar.2024.1438067. eCollection 2024.

本文引用的文献

1
Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.
Transl Lung Cancer Res. 2019 Nov;8(Suppl 3):S247-S264. doi: 10.21037/tlcr.2019.06.01.
4
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.
Br J Cancer. 2019 Oct;121(9):725-737. doi: 10.1038/s41416-019-0573-8. Epub 2019 Sep 30.
5
Molecular Mechanisms of Resistance to Tyrosine Kinase Inhibitors.
Curr Hematol Malig Rep. 2019 Oct;14(5):395-404. doi: 10.1007/s11899-019-00543-7.
6
CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC.
Cancer Res. 2019 Sep 1;79(17):4439-4452. doi: 10.1158/0008-5472.CAN-19-0024. Epub 2019 Jul 4.
8
Fibroblast growth factor receptors as treatment targets in clinical oncology.
Nat Rev Clin Oncol. 2019 Feb;16(2):105-122. doi: 10.1038/s41571-018-0115-y.
10
Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018.
Eur J Cancer. 2018 Nov;103:356-387. doi: 10.1016/j.ejca.2018.07.005. Epub 2018 Aug 9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验